Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Selective CETP Inhibition and PPAR{alpha} Agonism Increase HDL Cholesterol and Reduce LDL Cholesterol in Human ApoB100/Human CETP Transgenic Mice.

Autor: Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC

Publikováno v: Journal of Cardiovascular Pharmacology & Therapeutics; Jun2010, Vol. 15 Issue 2, p196-202, 7p

Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.

Autor: Finger JN; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Brusq JM; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Campobasso N; Structural and Biophysical Sciences, GlaxoSmithKline, Collegeville, PA, USA., Cook MN; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Deutsch J; Integrated Biological Platform Sciences, GlaxoSmithKline, Collegeville, PA, USA., Haag H; Integrated Biological Platform Sciences, GlaxoSmithKline, Collegeville, PA, USA., Harris PA; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Jenkins EL; Integrated Biological Platform Sciences, GlaxoSmithKline, Collegeville, PA, USA., Joglekar D; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Lich JD; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Maguire S; Integrated Biological Platform Sciences, GlaxoSmithKline, Collegeville, PA, USA., Nagilla R; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Rivera EJ; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Sun H; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Votta BJ; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Bertin J; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA., Gough PJ; Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA.

Publikováno v: Pharmacology research & perspectives [Pharmacol Res Perspect] 2017 Dec; Vol. 5 (6).

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Autor: Sujobert P; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Poulain L; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Paubelle E; INSERM UMR 1163, Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, 75015 Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, 75015 Paris, France; CNRS ERL 8254, 75015 Paris, France; Laboratory of Excellence GR-Ex, 75015 Paris, France., Zylbersztejn F; INSERM UMR 1163, Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, 75015 Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, 75015 Paris, France; CNRS ERL 8254, 75015 Paris, France; Laboratory of Excellence GR-Ex, 75015 Paris, France., Grenier A; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Lambert M; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Townsend EC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Brusq JM; GlaxoSmithKline Research Center, 91490 Les Ulis, France., Nicodeme E; GlaxoSmithKline Research Center, 91490 Les Ulis, France., Decrooqc J; INSERM UMR 1163, Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, 75015 Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, 75015 Paris, France; CNRS ERL 8254, 75015 Paris, France; Laboratory of Excellence GR-Ex, 75015 Paris, France., Nepstad I; Division for Hematology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway., Green AS; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Mondesir J; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Hospital MA; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Jacque N; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Christodoulou A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Desouza TA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Hermine O; INSERM UMR 1163, Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, 75015 Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, 75015 Paris, France; CNRS ERL 8254, 75015 Paris, France; Laboratory of Excellence GR-Ex, 75015 Paris, France., Foretz M; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Laboratory of Excellence GR-Ex, 75015 Paris, France., Viollet B; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Laboratory of Excellence GR-Ex, 75015 Paris, France., Lacombe C; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Mayeux P; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Moura IC; INSERM UMR 1163, Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, 75015 Paris, France; Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, 75015 Paris, France; CNRS ERL 8254, 75015 Paris, France; Laboratory of Excellence GR-Ex, 75015 Paris, France., Bouscary D; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France., Tamburini J; INSERM U1016, Institut Cochin, 75014 Paris, France; CNRS UMR8104, 75014 Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), 75013 Paris, France. Electronic address: jerome.tamburini@inserm.fr.

Publikováno v: Cell reports [Cell Rep] 2015 Jun 09; Vol. 11 (9), pp. 1446-57. Date of Electronic Publication: 2015 May 21.

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.

Autor: Mirguet O; Centre de Recherches François Hyafil, GlaxoSmithKline R&D , 25 Avenue du Québec, 91140 Villebon-sur-Yvette, France., Gosmini R, Toum J, Clément CA, Barnathan M, Brusq JM, Mordaunt JE, Grimes RM, Crowe M, Pineau O, Ajakane M, Daugan A, Jeffrey P, Cutler L, Haynes AC, Smithers NN, Chung CW, Bamborough P, Uings IJ, Lewis A, Witherington J, Parr N, Prinjha RK, Nicodème E

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2013 Oct 10; Vol. 56 (19), pp. 7501-15. Date of Electronic Publication: 2013 Sep 25.